Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 30;9(4):101432.
doi: 10.1016/j.adro.2023.101432. eCollection 2024 Apr.

Carbon Ion Radiation Therapy for Nonmetastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis

Yuhei Miyasaka  1   2 , Hidemasa Kawamura  1   2 , Hiro Sato  1   2 , Nobuteru Kubo  1   2 , Hiroyuki Katoh  3 , Hitoshi Ishikawa  4 , Hiroshi Matsui  2   5 , Yoshiyuki Miyazawa  5 , Kazuto Ito  5 , Kazuhiro Suzuki  2   5 , Tatsuya Ohno  1   2
Affiliations

Carbon Ion Radiation Therapy for Nonmetastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis

Yuhei Miyasaka et al. Adv Radiat Oncol. .

Abstract

Purpose: Treatment outcomes of definitive photon radiation therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC) are reportedly unsatisfactory. Carbon ion radiation therapy (CIRT) has shown favorable tumor control in various malignancies, including radioresistant tumors. Therefore, we retrospectively evaluated the clinical outcomes of CIRT for nmCRPC.

Methods and materials: Patients with nmCRPC (N0M0) treated with CIRT at a total dose of 57.6 Gy (relative biologic effectiveness) in 16 fractions or 51.6 Gy (relative biologic effectiveness) in 12 fractions were included. The castration-resistant status received a diagnosis based on prostate-specific antigen kinetics showing a monotonic increase during primary androgen deprivation therapy or the need to change androgen deprivation therapy. Clinical factors associated with patient prognosis were explored. Twenty-three consecutive patients were identified from our database. The median follow-up period was 63.6 months (range, 14.1-120).

Results: Seven patients developed biochemical relapse, 6 had clinical relapse, and 4 died of the disease. The 5-year overall survival, local control rate, biochemical relapse-free survival, and clinical relapse-free survival were 87.5%, 95.7%, 70.3%, and 75.7%, respectively. One patient with diabetes mellitus requiring insulin injections and taking antiplatelet and anticoagulant drugs developed grade 3 hematuria and bladder tamponade after CIRT. None of the patients developed grade 4 or worse toxicity.

Conclusions: The present findings indicate the acceptable safety and favorable efficacy of CIRT, encouraging further research on CIRT for nmCRPC.

PubMed Disclaimer

Conflict of interest statement

Kazuhiro Suzuki has potential financial conflicts of interest due to consultancies in Takeda Pharmaceutical, Astellas Pharma, Daiichi-Sankyo, AstraZeneca, Sanofi, Janssen, and Bayer and grants received from Takeda Pharmaceutical, Astellas Pharma, and Daiichi-Sankyo. Tatsuya Ohno has potential financial conflicts of interest due to research funding from Hitachi Ltd Hiroyuki Katoh has potential financial conflicts of interest due to research funding from Toshiba Energy Systems & Solutions Corporation.

Figures

Figure 1
Figure 1
Kaplan-Meir curves in 23 patients. (A) Overall survival (equal to prostate cancer-specific survival), (B) local control, (C) biochemical relapse-free survival, and (D) clinical relapse-free survival. The gray regions show 95% confidence intervals. Abbreviation: CIRT = carbon ion radiation therapy.
See this image and copyright information in PMC

References

    1. National Comprehensive Cancer Network (NCCN) Guidelines. Prostate Cancer version 2.2019 2019. Accessed July 18, 2019. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
    1. Akimoto T, Kitamoto Y, Saito JI, et al. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: Impact of pretreatment PSA value on radiotherapeutic outcomes. Int J Radiat Oncol Biol Phys. 2004;59:372–379. - PubMed
    1. Sanguineti G, Marcenaro M, Franzone P, Tognoni P, Barra S, Vitale V. Is there a “curative” role of radiotherapy for clinically localized hormone refractory prostate cancer? Am J Clin Oncol. 2004;27:264–268. - PubMed
    1. Ogawa K, Nakamura K, Sasaki T, et al. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: Clinical significance of nadir prostate-specific antigen value within 12 months. Int J Radiat Oncol Biol Phys. 2009;74:759–765. - PubMed
    1. Sasaki T, Nakamura K, Ogawa K, et al. Radiotherapy for patients with localized hormone-refractory prostate cancer: Results of the Patterns of Care Study in Japan. BJU Int. 2009;104:1462–1466. - PubMed

LinkOut - more resources